The accreditors of this session require that you periodically check in to verify that you are still attentive. Please click the button below to indicate that you are.
Credits: None available.
As a result of participating in this activity, learners will be better able to:
Release date: This activity was released 8/20/2022.
Termination date: The content of this activity remains eligible for CME Credit until 8/19/2025, unless reviewed or amended prior to this date.
Claiming Credit: Watch the entire presentation and complete the Improvement Plan/Evaluation.
Neurovations Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Neurovations Education designates this other activity (blended learning) for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity includes discussions of unlabeled or investigational uses of commercial and/or developmental products.
This activity includes discussions and explorations of new and evolving topics. Such inclusion includes adequate justifications of statements based upon current science, evidence and clinical reasoning.
[Presenter] Zachary McCormick discloses the following financial relationships within the past 24 months: Research: Avanos Medical, Boston Scientific, Relievant Medsystems, SPR Therapeutics; Consulting: FUSmobile, Saol Therapeutics, SI Bone, Stryker
No other person with control of, or responsibility for, the planning, delivery, or evaluation of accredited continuing education has, or has had within the past 24 months, financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships have been mitigated. Materials were reviewed in advance of the activity by person(s) that do not have conflicts of interest related to the content. In some cases, content may have been modified as part of the review and mitigation process. All clinical recommendations are evidence-based and free of commercial bias (e.g., peer-reviewed literature, adhering to evidence-based practice guidelines).
Release date: This activity was released 8/20/2022.
Termination date: The content of this activity remains eligible for CME Credit until 8/19/2025, unless reviewed or amended prior to this date.
Claiming Credit: Watch the entire presentation and complete the Improvement Plan/Evaluation.
Neurovations Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Neurovations Education designates this other activity (blended learning) for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity includes discussions of unlabeled or investigational uses of commercial and/or developmental products.
This activity includes discussions and explorations of new and evolving topics. Such inclusion includes adequate justifications of statements based upon current science, evidence and clinical reasoning.
Disclosure of Financial Relationships & Measures to Resolve of Conflicts of Interest
[Presenter] Zachary McCormick discloses the following financial relationships within the past 24 months: Research: Avanos Medical, Boston Scientific, Relievant Medsystems, SPR Therapeutics; Consulting: FUSmobile, Saol Therapeutics, SI Bone, Stryker
No other person with control of, or responsibility for, the planning, delivery, or evaluation of accredited continuing education has, or has had within the past 24 months, financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships have been mitigated. Materials were reviewed in advance of the activity by person(s) that do not have conflicts of interest related to the content. In some cases, content may have been modified as part of the review and mitigation process. All clinical recommendations are evidence-based and free of commercial bias (e.g., peer-reviewed literature, adhering to evidence-based practice guidelines).
You must be logged in and own this session in order to post comments.
Release date: This activity was released 8/20/2022.
Termination date: The content of this activity remains eligible for CME Credit until 8/19/2025, unless reviewed or amended prior to this date.
Claiming Credit: Watch the entire presentation and complete the Improvement Plan/Evaluation.
Neurovations Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Neurovations Education designates this other activity (blended learning) for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity includes discussions of unlabeled or investigational uses of commercial and/or developmental products.
This activity includes discussions and explorations of new and evolving topics. Such inclusion includes adequate justifications of statements based upon current science, evidence and clinical reasoning.
Disclosure of Financial Relationships & Measures to Resolve of Conflicts of Interest
[Presenter] Zachary McCormick discloses the following financial relationships within the past 24 months: Research: Avanos Medical, Boston Scientific, Relievant Medsystems, SPR Therapeutics; Consulting: FUSmobile, Saol Therapeutics, SI Bone, Stryker
No other person with control of, or responsibility for, the planning, delivery, or evaluation of accredited continuing education has, or has had within the past 24 months, financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships have been mitigated. Materials were reviewed in advance of the activity by person(s) that do not have conflicts of interest related to the content. In some cases, content may have been modified as part of the review and mitigation process. All clinical recommendations are evidence-based and free of commercial bias (e.g., peer-reviewed literature, adhering to evidence-based practice guidelines).